| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Manoj Kumar Gupta, Gayatri Gouda, Ramakrishna Vadd. Role of the Tumor Microenvironment in Mediating Resistance to Anti-HER2 Antibodies. Critical reviews in oncogenesis. vol 29. issue 4. 2024-07-11. PMID:38989737. |
trastuzumab functions by inhibiting her2 signaling pathways, leading to cell cycle arrest and induction of apoptosis. |
2024-07-11 |
2024-07-13 |
human |
| Archana M G, Anusree K S, Unnikrishnan B S, Reshma P L, Syama H P, Sreekutty J, Manu M Joseph, Sreelekha T . HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer. ACS applied materials & interfaces. vol 16. issue 20. 2024-05-23. PMID:38739808. |
hsirna@pgd nps deciphered competent cancer cell internalization, enhanced cytotoxicity mediated via the induction of apoptosis, and excellent downregulation of the overexpressing target her2 gene. |
2024-05-23 |
2024-05-27 |
Not clear |
| Catrin Heim, Leonie Hartig, Nadine Weinelt, Laura M Moser, Emilia Salzmann-Manrique, Michael Merker, Winfried S Wels, Torsten Tonn, Peter Bader, Jan-Henning Klusmann, Sjoerd J L van Wijk, Eva Rettinge. Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation. Molecular therapy. Oncology. vol 32. issue 2. 2024-05-06. PMID:38706988. |
chimeric antigen receptor (car)-based immunotherapies, such as the erbb2 (her2)-car-engineered natural killer (nk) cell line nk-92/5.28.z, provide antitumor cytotoxicity primarily through car-mediated cytotoxic granule release and thereafter-even in cases with low surface antigen expression or tumor escape-by triggering intrinsic nk cell-mediated apoptosis induction via additional ligand/receptors. |
2024-05-06 |
2024-05-08 |
Not clear |
| Chia-Hsien Shih, Yu-Hua Lin, Hao-Lun Luo, Wen-Wei Sun. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma. Frontiers in pharmacology. vol 15. 2024-04-04. PMID:38572425. |
numerous her2 adcs have demonstrated significant growth inhibition and induction of apoptosis in translational models of her2-overexpressing bladder cancer. |
2024-04-04 |
2024-04-06 |
human |
| Marie-Claire D Wasson, Jaganathan Venkatesh, Hannah F Cahill, Meghan E McLean, Cheryl A Dean, Paola Marcat. LncRNAs exhibit subtype-specific expression, survival associations, and cancer-promoting effects in breast cancer. Gene. vol 901. 2024-01-22. PMID:38219875. |
characterization of her2 + -specific lncrna linc01269 and tnbc-specific lncrna al078604.2 showed nuclear localization and altered expression of hundreds of genes enriched in cancer-promoting processes, including apoptosis, cell proliferation and immune cell regulation. |
2024-01-22 |
2024-01-25 |
Not clear |
| Tianbao Chen, Yuling Wang, Lijuan Zhu, Jingchun Wu, Jintang Lin, Wei Huang, Deyue Ya. Hybrid Membrane Camouflaged Chemodrug-Gene Nanoparticles for Enhanced Combination Therapy of Ovarian Cancer. ACS applied materials & interfaces. 2023-12-06. PMID:38056905. |
her2 asos can inhibit the expression of endogenous her2 genes and recover cancer cells' sensitivity to mito, which ultimately led to a high apoptosis rate of 75.7% in vitro. |
2023-12-06 |
2023-12-10 |
human |
| Koh Furugaki, Takaaki Fujimura, Hayato Mizuta, Takuya Yoshimoto, Takashi Asakawa, Yasushi Yoshimura, Shigeki Yoshiur. FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes. NPJ precision oncology. vol 7. issue 1. 2023-10-25. PMID:37880373. |
the combination of fgfr and targeted tkis enhanced cell growth inhibition and apoptosis induction in basal fgfr1- and fgf2-high protein expressing cells with alk-rearranged and epidermal growth factor receptor (egfr)-mutated nsclc, human epidermal growth factor receptor 2 (her2)-amplified breast cancer, or v-raf murine sarcoma viral oncogene homolog b1 (braf)-mutated melanoma by preventing compensatory extracellular signal-regulated kinase (erk) reactivation. |
2023-10-25 |
2023-11-08 |
human |
| Devra Olson, Janelle Taylor, Kelsi Willis, Kelly Hensley, Sean Allred, Margo Zaval, Lauren Farr, Robert Thurman, Nishi Jain, Renee Hein, Michelle Ulrich, Scott Peterson, Anita Kulukia. HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer. Cancer research communications. 2023-09-18. PMID:37721518. |
the combination was correlated with enhanced her2 pathway inhibition, decreased proliferation, and increased apoptosis. |
2023-09-18 |
2023-10-07 |
Not clear |
| Emmalyn Lecky, Atreyi Mukherji, Rebecca German, Gabriella Antonellis, Jia-Ren Lin, Michael Yorsz, Kelley E McQueeney, Jeremy Ryan, Kimmie Ng, Ewa Sicinska, Peter K Sorger, Anthony Letai, Patrick D Bhol. Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells. Science advances. vol 9. issue 25. 2023-06-23. PMID:37352344. |
using cultured cells and rapid ex vivo cultures of colon cancer patient-derived xenograft (pdx) models, we identify bak as a univariate correlate of apoptotic priming, find that poorly primed subpopulations can correspond to specific stages of the cell cycle, and, in some pdx models, identify increased expression of bcl-xl, mcl-1, or her2 in subpopulations that are poorly primed for apoptosis. |
2023-06-23 |
2023-08-14 |
Not clear |
| Chenyi Ren, He Cao, Jing Zheng, Wenjia Sun, Jianya Zho. [Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. vol 26. issue 4. 2023-05-15. PMID:37183644. |
her2 is the most active receptor in the her family and can combine with other members to form dimers, which can activate multiple signaling pathways and regulate cell proliferation, differentiation, migration and apoptosis. |
2023-05-15 |
2023-08-14 |
human |
| Guochuang Chen, Leli Zeng, Bo Bi, Xiuyu Huang, Miaojuan Qiu, Ping Chen, Zhi-Ying Chen, Yulong He, Yihang Pan, Yu Chen, Jing Zha. Engineering Bifunctional Calcium Alendronate Gene-Delivery Nanoneedle for Synergistic Chemo/Immuno-Therapy Against HER2 Positive Ovarian Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2023-03-18. PMID:36932888. |
especially, caaln-n induced apoptosis of skov3-luc cell via down-regulation of her2 signaling pathway and synergized with her2×cd3 to generate high antitumor response. |
2023-03-18 |
2023-08-14 |
human |
| Thomas A Werfe. Assessment of the Immune Response to Tumor Cell Apoptosis and Efferocytosis. Methods in molecular biology (Clifton, N.J.). vol 2543. 2022-09-10. PMID:36087258. |
orthotopic her2+ mammary tumors are established in immune-competent mice, followed by a single administration of lapatinib, a receptor tyrosine kinase inhibitor of her2, to the mice that induces widespread, transient apoptosis in the tumor microenvironment. |
2022-09-10 |
2023-08-14 |
mouse |
| Fan Shi, Yanli Liu, Xuexiao Zhou, Pei Shen, Ran Xue, Min Zhan. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug delivery. vol 29. issue 1. 2022-05-04. PMID:35506447. |
human epidermal growth factor receptor 2 (her2) regulates cell mitosis, proliferation, and apoptosis. |
2022-05-04 |
2023-08-13 |
human |
| Mattia Lunardi, Ahmed Al-Habbaa, Mahmoud Abdelshafy, Matthew G Davey, Ahmed Elkoumy, Sandra Ganly, Hesham Elzomor, Christian Cawley, Faisal Sharif, James Crowley, Michael Kerin, William Wijns, Aoife Lowery, Osama Solima. Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review. BMC cancer. vol 22. issue 1. 2022-04-13. PMID:35413811. |
more recently, new potential genetic markers unrelated to the her2 gene, and linked to known cardiomyopathy genes or to genes regulating cardiomyocytes apoptosis and metabolism, have been detected. |
2022-04-13 |
2023-08-13 |
human |
| Marco Macagno, Silvio Bandini, Elisabetta Bolli, Amanda Bello, Federica Riccardo, Giuseppina Barutello, Irene Fiore Merighi, Guido Forni, Alessia Lamolinara, Francesco Del Pizzo, Manuela Iezzi, Federica Cavallo, Laura Conti, Elena Quaglin. Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. Biomedicines. vol 10. issue 2. 2022-02-25. PMID:35203439. |
igg induced by rhut vaccine mainly acts by blocking her2 signaling, thus impairing cell cycle progression and inducing apoptosis of cancer cells, but other indirect effector mechanisms could be involved in the antibody-mediated protection. |
2022-02-25 |
2023-08-13 |
mouse |
| Héctor I Saldivar-Cerón, Olga Villamar-Cruz, Claire M Wells, Ibrahim Oguz, Federica Spaggiari, Jonathan Chernoff, Genaro Patiño-López, Sara Huerta-Yepez, Mayra Montecillo-Aguado, Clara M Rivera-Pazos, Marco A Loza-Mejía, Alonso Vivar-Sierra, Paola Briseño-Díaz, Alejandro Zentella-Dehesa, Alfonso Leon-Del-Rio, Alejandro López-Saavedra, Laura Padierna-Mota, María de Jesús Ibarra-Sánchez, José Esparza-López, Rosaura Hernández-Rivas, Luis E Arias-Romer. p21-Activated Kinase 1 Promotes Breast Tumorigenesis Frontiers in cell and developmental biology. vol 9. 2022-02-03. PMID:35111748. |
we found a strong correlation between pak1 and camkii expression in human breast cancer samples, and combined inhibition of pak1 and camkii with small-molecule inhibitors was synergistic and induced apoptosis more potently in her2 positive and triple negative breast cancer (tnbc) cells. |
2022-02-03 |
2023-08-13 |
mouse |
| Adina Gerson-Gurwitz, Nathan P Young, Vikas K Goel, Boreth Eam, Craig R Stumpf, Joan Chen, Sarah Fish, Maria Barrera, Eric Sung, Jocelyn Staunton, Gary G Chiang, Kevin R Webster, Peggy A Thompso. Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors. Frontiers in oncology. vol 11. 2021-12-13. PMID:34900714. |
in solid tumor models driven by alterations in her2 or fgfr1/2, downregulation of oncoprotein expression by zotatifin induces sustained pathway-dependent anti-tumor activity resulting in potent inhibition of cell proliferation, induction of apoptosis, and significant |
2021-12-13 |
2023-08-13 |
human |
| Qifan Yang, Xianxiu Qiu, Xiaozhe Zhang, Yingting Yu, Na Li, Xing Wei, Guoqin Feng, Yan Li, Yanxiang Zhao, Renxiao Wan. Optimization of Beclin 1-Targeting Stapled Peptides by Staple Scanning Leads to Enhanced Antiproliferative Potency in Cancer Cells. Journal of medicinal chemistry. vol 64. issue 18. 2021-11-23. PMID:34506131. |
optimized peptides showed potent antiproliferative efficacy in cancer cells that overexpressed egfr and her2 by inducing necrotic cell death but not apoptosis. |
2021-11-23 |
2023-08-13 |
Not clear |
| Man Zhu, Xiaoyu Tang, Zhengyan Gong, Wenjuan Tang, Yanmin Zhan. TAD1822-7 induces ROS-mediated apoptosis of HER2 positive breast cancer by decreasing E-cadherin in an EphB4 dependent manner. Life sciences. vol 285. 2021-11-15. PMID:34520770. |
tad1822-7 induces ros-mediated apoptosis of her2 positive breast cancer by decreasing e-cadherin in an ephb4 dependent manner. |
2021-11-15 |
2023-08-13 |
Not clear |
| Man Zhu, Xiaoyu Tang, Zhengyan Gong, Wenjuan Tang, Yanmin Zhan. TAD1822-7 induces ROS-mediated apoptosis of HER2 positive breast cancer by decreasing E-cadherin in an EphB4 dependent manner. Life sciences. vol 285. 2021-11-15. PMID:34520770. |
inhibition of her2 or ephb4 is discovered to induce ros-dependent apoptosis by decreasing e-cadherin expression in skbr3 and mda-mb-453 cells. |
2021-11-15 |
2023-08-13 |
Not clear |